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The risk of stroke in end-stage renal disease (ESRD) on renal replacement therapy 
(RRT) is up to 10-fold greater than the general population. However, whether this 
increased risk differs by RRT modality is unclear.  
Methods 
We used data contained in the Scottish Renal Registry and the Scottish Stroke Care 
Audit to identify stroke in all adult patients who commenced RRT for ESRD from 2005 
to 2013. Incidence rate was calculated and regression analyses performed to identify 
variables associated with stroke. We explored effect of RRT modality at initiation and 
cumulative dialysis exposure by time dependent regression analysis, using transplant 
recipients as the reference group.   
Results 
A total of 4,957 patients commenced RRT for ESRD. Median age was 64.5years, 
41.5% were female and 277 patients suffered a stroke (incidence rate was 18.6/1000 
patient-years). Patients who had stroke were older, had higher blood pressure and 
were more likely to be female and have diabetes. On multivariable regression older 
age, female sex, diabetes and higher serum phosphate were associated with risk of 
stroke. RRT modality at initiation was not. On time dependent analysis, haemodialysis 




In patients with ESRD who initiate renal replacement therapy, haemodialysis use 
independently increases risk of stroke compared to transplantation. Use of peritoneal 





The incidence of stroke increases with declining kidney function and is highest rate in 
those with end-stage renal disease (ESRD)(1,2). The choice of renal replacement 
therapy (RRT) in ESRD is a joint decision between clinician and patient, taking 
comorbidity and patient preference into account. Haemodialysis (HD) is the most 
common modality, peritoneal dialysis (PD) may not be practical for some patients and 
renal transplantation may not be possible due to operative risk and availability of 
organs. Each of these RRT options causes physiological and pharmacological 
stresses which may differentially influence stroke risk. Previous reports have 
described stroke incidence rates in RRT: highest in HD(3–7), followed by PD(8,9) and 
lowest in those with a functioning renal transplant(10–12).  Whilst RRT is a life-saving 
treatment in ESRD, recent data have suggested that initiating dialysis may be 
associated with a rise in stroke incidence(9), putting forward the hypothesis that the 
process of HD may be associated with increased stroke risk.  
To explore whether a particular dialysis modality is associated with differentially higher 
stroke risk, we performed analyses using data from the Scottish Renal Registry (SRR) 
and Scottish Stroke Care Audit (SSCA) to analyse the influence of treatment modality 
on stroke risk in all adult patients commencing RRT for ESRD between 2005 and 2013 
in Scotland.  
Materials and Methods  
Datasets 
The Scottish Renal Registry (SRR) is a nation-wide dataset, contributed to by all nine 
adult renal units in Scotland(13). Data include baseline demographics, primary renal 
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diagnosis, renal replacement modality history, laboratory data and an annual census 
of clinical variables.  All patients receiving RRT for ESRD are included. The SRR 
Scottish Mortality Audit in Renal Replacement Therapy (SMARRT), which consistently 
achieves  ≥95% completeness of data(14), ensured capture of enhanced data around 
primary cause of death for all ESRD patients.   
The Scottish Stroke Care Audit(15) was established in 2002 to monitor performance 
of stroke care against guideline based clinical standards throughout Scotland. Data 
are collected on patient demographics, stroke subtype and outcomes. This dataset 
has provided complete coverage of all hospitals managing acute stroke since 2005.  
The Scottish Morbidity Records 01 (SMR01) collects data on hospital discharges since 
1968(16) . Since 1989 SMR01 has been used to plan financial management of 
hospitals in order to ensure high completion rate. Internal audit of these data supports 
overall 89% accuracy for Main Condition diagnosis -  a result which has remained 
stable for over 25 years(17).   
All three datasets were linked, over the period 1st January 2005 to 31st December 
2013, to create a dataset allowing determination of the following:  (1) stroke incidence 
rates by modality; (2) factors associated with stroke in ESRD and (3) the influence of 
exposure to each dialysis modality on stroke risk.  
Definitions 
End-Stage Renal Disease 
All patients commencing RRT for ESRD in Scotland are recorded within the SRR. We 
analysed adults (those ≥18 years at initiation) who began RRT for ESRD during our 
study period. Therefore, we excluded all patients commencing RRT out-with Scotland 
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and all those who began RRT for acute kidney injury (AKI) recovering within 90days, 
unless RRT was reinitiated for ESRD during the study period. The date of commencing 
RRT for ESRD was used as date of cohort entry in all cases.  
Modality of renal replacement therapy 
The first RRT modality was extracted from the SRR (hospital or home HD, automated 
or continuous ambulatory peritoneal dialysis and pre-emptive kidney transplant). 
Further, we calculated RRT modality use on a month-by-month basis to assess 
exposure over the study period in time-dependent analysis. 
Stroke Incidence Rate 
The stroke incidence rate is presented as events per 1000 patient-years, calculated 
using stroke events as the numerator and cumulative follow-up in years as the 
denominator. Patient follow-up continued until first episode of stroke, death or end of 
follow-up, whichever came first. We present the total incidence rate of all ESRD 
patients and incidence rates split by RRT modality using the first RRT modality. We 
calculated the stroke incidence rate over three time periods; during the entire follow-
up, during the first 90 days of commencing RRT (‘incident RRT population’) and, 
finally, after the first 90 days of RRT (‘prevalent RRT population’).   
Stroke 
All non-fatal and fatal strokes were included in our analyses.  From the SSCA we 
extracted the date and subtype of first stroke during the study period. To ensure 
complete capture of stroke, SMR01 was interrogated for presence and dates of ICD-
10 codes pertaining to stroke episodes, (I60, I61, I62.9, I63 and I64) excluding 
subdural and extradural haemorrhage. Using SMARRT data within the SRR all cases 
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where ‘Cerebrovascular accident, ERA-EDTA mortality code 22’ was listed as the 
primary cause of death were extracted  
Baseline Characteristics 
The SMR01 was interrogated from 01 January 1981 until 31 December 2013 for 
presence of ICD-10 codes relating to atrial fibrillation/flutter (I48), ischaemic heart 
disease (I21, 24, 24.8, I24.9, I25, I25.1, I25.2, I25.5 and I25.8), diabetes mellitus (E10 
and E11), hypercholesterolaemia (E78), obesity (E66), smoking (F17) and 
hypertension (I10 and I15). To prevent overlap of diagnoses, ICD codes for prior stroke 
(I60, I61, I62.9, I63 and I64) were pulled from 1981 until date of first stroke in those 
who suffered stroke, or until 31.12.2013 in those who do not.  
Using patient postcode, the Scottish Government urban-rural classification 
(http://www.isdscotland.org/Products-and-Services/GPD-Support/Geography/Urban-
Rural-Classification/) and divisions of socioeconomic deprivation (Scottish Index of 
Multiple Deprivation (SIMD)) (http://www.gov.scot/Topics/Statistics/SIMD) were 
calculated. Using postcode at commencement of RRT, deprivation quintiles were 
categorized into most (quintiles 1–2) or least deprived (quintiles 3–5). The 6-fold 
urban-rural classification was subdivided into urban (population >3000) and rural 
(population <3000).  
Clinical and Lab Values 
The annual census collects data on blood pressure, weight, use of erythropoietin –
stimulating agents and blood results; namely blood haemoglobin, serum albumin, 
phosphate, adjusted calcium and quality of dialysis as assessed by urea reduction 
ratio (in those receiving HD). Data were collected and have been provided as a median 
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(IQR) of all results over the entire study period or until date of stroke, whichever comes 
first.  
Statistical Analyses 
Data are presented as medians (IQR) for continuous data or total number (%) for 
categorical data. Demographics are compared using Mann-Whitney U or Chi-Squared 
testing as appropriate. In keeping with previous studies we examined factors 
influencing time to stroke by applying a Cox proportional hazard model to all variables, 
including the initial RRT modality. A multivariable model using variables relevant to 
stroke was then constructed. A backward stepwise selection procedure was applied, 
removing variables with p value >0.1. With the knowledge that RRT modality can 
change over time, we expressed the dialysis modality as a time dependent covariate 
allowing analysis of the cumulative exposure of each dialysis modality on the risk of 
stroke. Four adjusted multivariable models were constructed: Model 1, adjusting for 
age and sex; Model 2, model 1 adjustments plus prior atrial fibrillation and stroke; and 
Model 3, model 2 adjustments plus prior ischaemic heart disease, hypertension, 
diabetes and serum phosphate. All analyses were completed using SAS v9.4. 
Ethical Approval 
The datasets used in this manuscript work within the “NHS Code of Practice on 
Protecting Patient Confidentiality” which incorporates the requirements of statute and 
common law including the Data Protection Act, the Human Rights Act and the Adults 
with Incapacity (Scotland) Act. Access and use of the data for the purpose of this study 
was approved following a NSS proportionate governance review by the Privacy 




4,957 adult patients commenced renal replacement therapy for end-stage renal 
disease in Scotland during our study period. The median age (IQR) at commencing 
RRT was 64.5(23.5) years, 2068(41.5%) were female. 3913(78.9%) began on HD 
(3908 in-centre, 5 at home) 843(17%) peritoneal dialysis (562 continuous ambulatory 
peritoneal dialysis, 281 automated peritoneal dialysis) and 201(4.1%) received a pre-
emptive kidney transplant. Median duration of follow-up was 856(1354) days. 
Demographics are outlined in Tables 1 and 2.  
There were 277 strokes during the follow-up period (5.6% of patients). 38(13.75%) 
were haemorrhagic, and the remainder ischaemic or unspecified (including those 
listed as primary cause of death). 21 (7.6%) strokes were fatal at diagnosis. 
Cumulative follow-up was 14,926.9 years. Unadjusted stroke incidence rate for all 
ESRD patients was 18.6 strokes per 1000 patient-years. Using first RRT modality the 
stroke incidence rate for each of HD, peritoneal dialysis and renal transplant is 21.2, 
13.2 and 5.4 per 1000 patient-years, respectively, p <0.0001 (Figure 1).  We 
recalculated incidence rate for each modality based on those who suffer stroke within 
the first 90 days of commencing RRT or who suffer stroke from 90days onwards. The 
incidence rate of stroke in the incident population (≤90days of RRT) was 35.0, 24.5 
and 19.9 per 1000 patient-years for each of HD, PD and transplant, respectively 
(p=0.04). In the prevalent population, rates were 19.9, 12.5 and 4.3 per 1000 patient-
years, for HD, PD and transplant respectively (p<0.01).  
Patients who suffered stroke were older (70.6 vs 64 years, p<0.0001), more likely to 
be female (49.1% vs 41.1%, p=0.01), have diabetic nephropathy (31.1% vs 22.9%, 
p<0.01), a past medical history of diabetes (46.2% vs 35.8%, p<0.001) and 
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hypercholesterolaemia (18.4% vs 13.7%, p=0.04). Clinical variables revealed higher 
median systolic blood pressure (144 vs 139mmHg, p<0.01), lower body weight (72.5 
vs 73.9 kg, p<0.01), lower serum albumin (36 vs 37g/L, p=0.03) and higher serum 
phosphate (1.55 vs 1.46mmol/L, p<0.01) in those who suffer from stroke.    
There were significant differences between patients who commenced HD, PD and 
renal transplant as their first modality (table 2).  
Risk of Stroke 
Univariable regression revealed age, female sex, presence of atrial fibrillation, prior 
stroke & diabetes were significantly associated with stroke (p<0.01).  In addition, 
higher phosphate and systolic blood pressure was associated with greater risk, as was 
lower body weight, lower haemoglobin, lower serum calcium and use of HD as first 
RRT modality, p≤0.01. After multivariable adjustment age, female sex, diabetes and 
higher serum phosphate associated with stroke (Table 3). The initial RRT modality 
was not significant.  
On time dependent analysis, both HD and PD exposure were associated with greater 
unadjusted stroke risk than renal transplant. Models 1, 2 and 3 progressively adjust 
for demographics, covariates relevant to stroke and covariates relevant to 
cardiovascular disease. HD but not PD was associated with increased risk in the fully 
adjusted model (Table 4).   
Discussion 
In this population based national study we report the high burden of stroke in patients 
with ESRD and the impact of both conventional and renal-specific factors associated 
with stroke occurrence. Of interest, we found that exposure to HD, but not peritoneal 
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dialysis as the modality of renal replacement therapy increases the risk of stroke 
compared to renal transplantation, after correcting for demographics and risk factors. 
This suggests that treatment with HD may be an additional stroke risk factor. Stroke 
is up to 10 times more common in those with ESRD(7), making the findings of our 
study noteworthy for nephrologist discussing choice of dialysis modality at the low 
clearance clinic.  
Prolonged exposure to PD is often limited to reduce the risk of devastating 
complications such as encapsulating peritoneal sclerosis(18). With increasing data 
describing the vascular driven end-organ damage associated with HD exposure(19) it 
may be time to consider a similar approach in HD.   
Incidence of stroke 
We report an incidence rate of 18.6/1000 patient-years in all incident ESRD patients 
over a 9 year period. Although high, this is in keeping with previous literature in 
ESRD(4,20). For context, the unadjusted stroke rate in Scotland’s population over the 
study period is 2.4/1000 patient-years(21), demonstrating a 7.5 fold increase in 
incidence for those with ESRD. Split by modality the incidence rate is greatest in the 
order HD, 21.2/1000 patient-years; PD, 13.2/1000 patient-years; and finally transplant 
at 5.4/1000 patient-years. Those commencing RRT are classified as the ‘incident’ 
ESRD population until their first 90 days of RRT and ‘prevalent’ thereafter. For interest 
we calculated the stroke incidence rate for the incident and prevalent groups and found 
a higher stroke incidence in the incident population receiving all forms of RRT, when 
compared to the prevalent (HD, 35.0 vs 19.9; PD, 24.5 vs 12.5; transplant 20.7 vs 4.3 
per 1000 patient-years). This finding is intriguing. The rise in stroke incidence in the 
first 90 days following dialysis initiation has been previously reported(9) , but this is a 
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new finding the transplant population. At the time of transplant patients receive 
significant doses of immunosuppressive drugs, often large and rapid fluid and/or blood 
pressure shifts and a general anaesthetic with its associated cardiovascular stress. 
Any one of these stressors could act as a physiological ‘stress-test’ capable of 
inducing a vascular event in a vulnerable patient. However, understanding the 
mechanism behind this is out with the scope of this study.   
‘Static’ Risk Factors for stroke 
Cardiovascular disease is the leading cause of morbidity and mortality in ESRD and 
has been extensively studied. However, the impact from conventional risk factors on 
cerebrovascular disease in ESRD varies(4,5,22–25). For instance, atrial fibrillation –a 
treatable risk factor of stroke in the general population- is inconsistently reported as a 
risk factor in ESRD(6,24,26–28) and whilst this was associated with stroke on 
univariable testing, this association was not present on multivariable analysis, 
presumably due to the close association of atrial fibrillation with other vascular 
comorbidity and age. Furthermore, the use of warfarin for stroke prevention has been 
brought into doubt. Studies have suggested harm without reduction in stroke risk from 
use of warfarin(26) in ESRD. Unfortunately, no randomised control data exist to guide 
anticoagulation use. Therefore, risk factors unique to ERSD are often explored. We 
describe, as others have(4,23,29), an increased stroke risk with lower weight, lower 
haemoglobin and higher serum phosphate. Although use of HD as the initial RRT 
modality is associated with stroke on univariable analysis, this is lost in the adjusted 
model. In this model, age, female sex, diabetes and higher serum phosphate are 
predictive of stroke.    
Impact of Modality exposure on stroke risk 
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Choice of RRT modality is a decision made between the patient and clinician taking 
into consideration physical fitness to undergo treatments, and the likelihood of 
sustainability(30). For example, those with extensive cardiac disease are rarely 
considered for transplantation, and those with significant functional disabilities rarely 
opt for a home based treatment. Therefore, patients receiving each dialysis modality 
are inherently different.  
Data suggest the initiation of dialysis increases the risk of stroke with a 2 to 7 fold 
increase, ranging from those who commence PD to those who undergo in-hospital 
initiation of HD(9). Whilst the increased stroke rate at HD initiation may be a 
consequence of cumulative insults peaking at HD, further data suggest the association 
of HD with stroke continues beyond this. Specifically, stroke events are temporally 
associated with HD session(31), HD is believed to alter cerebral blood flow(32–34) 
and intradialytic hypotension is associated with small vessel disease and frontal 
atrophy(35). In fact, even short-term HD exposure has been associated with an 
increased stroke risk. A retrospective registry-based study from Taiwan reported an 
increase in the risk of incident stroke in those who had suffered an episode of AKI 
requiring temporary HD – a finding that persisted despite correction for residual CKD. 
The impact of transient HD was comparable to being diabetic(36). These data suggest 
exposure to HD may exert an unwanted cerebrovascular effect; an effect less well 
reported in those on PD.  
A recent prospective study from China(8)  examined the effect of dialysis modality on 
stroke risk, describing an approximate doubling in adjusted risk for stroke in those on 
HD compared to PD (HR 2.03, p=0.005). Whilst interesting, their results are not directly 
comparable to ours due to differences in methodology; specifically they examined their 
prevalent dialysis population only, omitted transplant recipients and - most importantly 
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- used the first dialysis modality throughout their analyses, without adjusting for 
modality switching.  
HD is a life-prolonging therapy, essential to over 25,000 patients in the UK alone. Data 
supporting a cerebrovascular ‘side-effect’ must lead to intervention in to mitigate this 
effect. Recently, the effect of cooled vs normothermic dialysis on white matter 
microstructure(37) has been observed. A pattern of ischaemic injury was observed at 
12 months in those with normothermic, but not those who underwent cooled HD, 
concluding that the haemodynamic stress of HD was responsible.  Patients can find 
cooled HD uncomfortable, limiting its use.  Another option therefore would be the use 
of PD, or switching to PD in cases of cerebral injury. PD is effective at reducing serum 
glutamate(38), with the ability to reduce infarct size in animal models(39). The relative 
ease of PD catheter insertion, haemodynamic stability, absence of anticoagulation and 
portability of this treatment would make initiating, or transiently switching to, peritoneal 
dialysis on arrival to the stroke unit an attractive treatment strategy for stroke in ESRD. 
Data confirming its efficacy in humans are lacking, and trials are desperately needed.   
Limitations 
We acknowledge this study has limitations. Firstly, our data are retrospective therefore 
we cannot prove causation but only describe association. Further, after multivariable 
adjustment, we saw no increase in stroke risk in those on PD compared to 
transplantation. However, confidence intervals were wide so a small increase cannot 
be completely excluded. We lack data on the reason for modality switching, which may 
affect our results. For example, deterioration in health could result in switching to 
hospital HD, thus overestimating an effect of HD. However, adjustment in our 
regression analyses for cardiovascular comorbidity should limit this effect.  In addition, 
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we do not have access to prescription records to examine the effect of warfarin, or 
anti-platelet therapy on stroke risk. However, as INR is not held in any dataset the use 
of prescription data would be limited. Unfortunately, we did not have access to multiple 
BP measurements to sufficiently analyse the effect of BP magnitude on stroke risk. 
Rather, we used the coded diagnosis of hypertension in our analyses. Despite this 
limitation, we believe this method is superior as it allows consideration for prior 
exposure to hypertension which could be missed from isolated readings.  Further, we 
have used coded diagnoses to define stroke. However, both the SSCA – which is 
internally validated by stroke physicians – and the SMR01, which is regularly audited 
confirming an approximately 90% accuracy rate, are validated sources. Finally, whilst 
the rise in stroke incidence within the first 90 days following transplant is an interesting 
and novel finding in our study, we acknowledge the small absolute numbers of stroke 
in our transplant group which under-power any formal assessment of this difference.  
Conclusions 
Our study confirms the high incidence rate of stroke in our UK-based study of patients 
commencing RRT for ESRD. Further, it has re-affirmed the rate of stroke is higher in 
those on HD followed by PD and transplant having the lowest rate of all ESRD 
treatment modalities. Conventional, in addition to renal specific factors are associated 
with stroke. Our novel finding, that exposure to HD increases risk for stroke, despite 
adjustment for age, sex and cardiovascular comorbidity in the incident ESRD 
population is alarming.  There is an urgent need for further study of the effects of HD 
on the cerebral circulation and trials of interventions to reduce this risk.  
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  No Stroke Stroke All p value 
N 4680 277 4957   
Median age, years (IQR) 64 (24.1) 70.6 (15) 64.5(23.5) <0.0001 
Female (%) 1922 (41.1) 136 (49.1) 2068 (41.5) 0.010 
Primary Renal Diagnosis (%)         
       Glomerulonephritis 690 (14.7) 26 (9.4) 716 (14.4) 0.014 
       Interstitial disease 1019 (21.8) 38 (13.7) 1057 (21.3) 0.001 
       Multisystem  1112 (23.8) 79 (28.5) 1191 (24.0) 0.082 
       Diabetes 1071 (22.9) 86 (31.1) 1157 (23.3) 0.003 
       Other 778 (16.6) 47 (17.0) 825 (16.6) 0.868 
       Missing 10 (0.2) 1 (0.4) 11 (0.2)  
Urban Rurality Status (%)     
       Urban 3861 (82.5) 232 (83.8) 4093 (82.6)  
       Rural 819 (17.5) 45 (16.3) 864 (17.4) 0.626 
Deprivation Status (%)     
       Least (SIMD quintiles 3-5) 3464 (74.0) 213 (76.9) 3677 (74.2)  
       Most (SIMD quintiles 1&2) 1216 (26) 64 (23.1) 1280 (28.8) 0.323 
First RRT Modality (%)     
       Haemodialysis 3685 (78.7) 228 (82.3) 3913 (78.9) 0.172 
       Peritoneal Dialysis 798 (17.1) 45 (16.3) 843 (17.0) 0.805 
       Transplant 197 (4.2) 4 (1.4) 201 (4.1) 0.018 
Past Medical History (%)     
       Atrial Fibrillation 185 (4.0) 17 (6.1) 202 (4.1) 0.085 
       Ischaemic Heart Disease 1449 (31.0) 90 (32.5) 1539 (31.1) 0.641 
       Stroke 122 (2.6) 12 (4.3) 134 (2.7) 0.123 
       Diabetes 1677 (35.8) 128 (46.2) 1805 (36.4) 0.001 
       Hypercholesterolaemia 643 (13.7) 51 (18.4) 694 (14.0) 0.040 
       Obesity 316 (6.8) 19 (6.9) 335 (6.8) 0.903 
       Smoking 307 (6.6) 14 (5.1) 321 (6.5) 0.380 
       Hypertension 3249 (69.4) 197 (71.1) 3446 (69.5) 0.686 
Clinical Variables, median (IQR)     
       SBP, mmHg 139 (30.0) 144 (30.0) 139.5 (30.0) 0.001 
       DBP, mmHg 71 (19.0) 70 (20.5) 71 (19.0) 0.902 
       Weight, kg 73.9 (23.9) 72.5 (26.2) 73.8 (23.9) 0.007 
       Use of ESA 3272 (69.9) 188 (67.9) 3460 (69.8) 0.501 
Laboratory Variables, median (IQR)     
       Haemoglobin, g/dL 11.3 (1.9) 11.2 (1.8) 11.3 (1.8) 0.358 
       Serum Albumin, g/L 37 (7.0) 36 (7.5) 37 (7.0) 0.025 
       Serum Phosphate, mmol/L 1.46 (0.6) 1.55 (0.6) 1.46 (0.6) 0.002 
       Serum Adjusted Calcium, mmol/L 2.36 (0.2) 2.34 (0.2) 2.35 (0.2) 0.022 
       Urea Reduction Ratio (HD only) 70.5 (10.0) 70 (12.5) 70.5 (10) 0.896 
Death at fup 2412 (51.5) 238 (85.9) 2650 (53.5) <0.0001 
 
Table 1 Baseline demographics of all end-stage renal disease patients, no stoke vs all stroke. IQR, 
Interquartile Range; SIMD, Scottish Index of Multiple Deprivation; RRT, Renal Replacement Therapy; 
SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoietin-stimulating agent.  
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 HD  p-value PD p-value Transplant 
n 3913  843  201 
Median age, years (IQR) 66.7 (21.7) <0.0001 57.3 (24.2) <0.0001 44.3 (20.8) 
Female (%) 1585 (40.5) 0.015 374 (44.4) 0.237 99 (49.3) 
Primary Renal Diagnosis (%)      
       Glomerulonephritis 509 (13.0) 0.003 165 (19.6) 0.694 42 (20.9) 
       Interstitial disease 732 (18.7) <0.0001 235 (27.9) <0.0001 90 (44.8) 
       Multisystem  1027 (26.3) <0.0001 140 (16.6) 0.107 24 (11.9) 
       Diabetes 962 (24.6) <0.0001 170 (20.2) 0.012 25 (12.4) 
       Other 673 (17.2) 0.007 132 (15.7) 0.045 20 (10.0) 
       Missing 10 (0.3)  1 (0.1)  0  
Urban Rurality Status (%)      
       Urban 3303 (84.4)  631 (74.9)  159 (79.1) 
       Rural 610 (15.6) 0.048 212 (25.2) 0.234 42 (20.9) 
Deprivation Status (%)      
       Least (SIMD quintiles 3-5) 2838 (72.5)  674 (80.0)  165 (82.1) 
       Most (SIMD quintiles 1&2) 1075 (27.5) 0.003 169 (20.1) 0.554 36 (17.9) 
Past Medical History (%)      
       Atrial Fibrillation 182 (4.7) 0.003 19 (2.3) 0.151 1 (0.5) 
       Ischaemic Heart Disease 1309 (33.5) <0.0001 223 (26.5) <0.0001 7 (3.5) 
       Stroke 116 (3.0) 0.065 17 (2.0) 0.224 1 (0.5) 
       Diabetes 1515 (38.7) <0.0001 252 (29.9) 0.01 38 (18.9) 
       Hypercholesterolaemia 552 (14.1) 0.022 127 (15.1) 0.011 15 (7.5) 
       Obesity 292 (7.5) <0.001 41 (4.9) 0.013 2 (1.0) 
       Smoking 259 (6.6) 0.284 54 (6.4) 0.393 8 (4.0) 
       Hypertension 2706 (69.2) <0.001 636 (75.4) <0.0001 104 (51.7) 
Clinical Variables, median (IQR)      
       SBP, mmHg 139.5 (30.0) 0.420 139 (30.0) 0.389 153.3 (38.5) 
       DBP, mmHg 70.5 (19.0) 0.078 75 (18.3) 0.113 90 (19.0) 
       Weight, kg 73.8 (24.3) 0.787 73.9 (19.9) 0.854 77.8 (23.5) 
       Use of ESA 2865 (73.2) <0.0001 591 (70.1) <0.0001 4 (2.0) 
Laboratory Variables, median (IQR)      
       Haemoglobin, g/dL 11.2 (1.8) <0.0001 11.7 (1.5) <0.0001 12.3 (2.4) 
       Serum Albumin, g/L 36 (7.5) <0.0001 38 (7.5) <0.0001 40 (6.0) 
       Serum Phosphate, mmol/L 1.47 (0.6) <0.0001 1.49 (0.5) <0.0001 1.01 (0.4) 
       Serum Adjusted Calcium, mmol/L 2.35 (0.2) <0.0001 2.38 (0.2) 0.179 2.39 (0.2) 
Stroke cases  228 (5.8) 0.018 45 (5.3) 0.04 4 (2.0) 
Death at fup 2314 (59.1) <0.0001 328 (38.9) <0.0001 8 (4.0) 
 
Table 2 Baseline demographics of patients split by initial RRT modality. Mann-Whitney U or Chi-square 
testing are applied, comparing HD to transplant, and PD to transplant. IQR, Interquartile Range; SIMD, 
Scottish Index of Multiple Deprivation; RRT, Renal Replacement Therapy; SBP, systolic blood pressure; 





 Univariate Regression Multivariate Regression 
  HR (95% CI) p value HR (95% CI) p value 
Age per year 1.05(1.04-1.06) <0.0001 1.05(1.04-1.06) <0.0001 
Female (%) 1.41(1.11-1.78) 0.004 1.41(1.10-1.82) 0.007 
Primary Renal Diagnosis (%)         
       Glomerulonephritis 0.55(0.37-0.83) 0.004     
       Interstitial disease 0.46(0.33-0.65) <0.0001     
       Multisystem  1.53(1.18-1.99) 0.001     
       Diabetes 1.61(1.25-2.08) <0.001     
       Other 1.07(0.78-1.47) 0.664     
Urban Rurality Status (%)         
       Rural 0.88(0.64-1.21) 0.430     
Deprivation Status (%)         
       Least (SIMD quintiles 3-5) 1.11(0.84-1.47) 0.457     
First RRT Modality (%)a          
       Haemodialysis 3.74(1.39-10.05) 0.009 - - 
       Peritoneal Dialysis 2.46(0.89-6.85) 0.084 - - 
Past Medical History (%)         
       Atrial Fibrillation 2.21(1.35-3.61) 0.002 - - 
       Ischaemic Heart Disease 1.10(0.86-1.42) 0.442 0.79(0.60-1.04) 0.094 
       Stroke 1.80(1.01-3.22) 0.046 - - 
       Diabetes 1.67(1.32-2.12) <0.0001 1.81(1.40-2.34) <0.0001 
       Hypercholesterolaemia 1.34(0.99-1.82) 0.057     
       Obesity 1.01(0.63-1.61) 0.968     
       Smoking 0.78(0.46-1.33) 0.362     
       Hypertension 0.95(0.73-1.23) 0.694 - - 
Clinical Variables, median (IQR)         
       SBP, mmHg 1.01(1.01-1.02) 0.001     
       DBP, mmHg 1.00(0.99-1.01) 0.722     
       Weight, kg 0.98(0.97-0.99) <0.001     
       Use of ESA 0.45 (0.35-0.57) <0.0001   
Laboratory Variables, median (IQR)         
       Haemoglobin, g/dL 0.79(0.72-0.87) <0.0001     
       Serum Albumin, g/L 0.93(0.90-0.95) <0.0001     
       Serum Phosphate, mmol/L 1.91(1.48-2.46) <0.0001 2.03(1.58-2.60) <0.0001 
       Serum Adjusted Calcium, mmol/L 0.16 (0.07-0.39) <0.0001     
 
Table 3 Variables associated with time to all stroke in all end-stage patients, unadjusted and adjusted. 
Variables were selected for the MV model on basis of clinical relevance to stroke risk in ESRD and 
modelled using a backward stepwise selection procedure (removal p>0.1). HR, hazard ratio; 95%CI, 
95% confidence interval; SIMD, Scottish Index of Multiple Deprivation; RRT, Renal Replacement 
Therapy; SBP, systolic blood pressure; DBP, diastolic blood pressure; ESA, erythropoietin-stimulating 




  Unadjusted  Model 1  Model 2  Model 3 
  
 
HR (95%CI) p-value 
 
HR (95% CI) p-value 
 
HR (95% CI) p-value 
 










       Haemodialysis 
 
5.57 (3.07-10.10) <0.0001 
 
2.77 (1.49-5.18) 0.001 
 
2.70 (1.45-5.04) 0.002 
 
1.95 (1.03-3.71) 0.041 
       Peritoneal Dialysis 
 
4.46 (2.16-8.39) <0.0001 
 
2.57 (1.29-5.15) 0.008 
 
2.52 (1.26-5.04) 0.009 
 





1.04 (1.03-1.05) <0.0001 
 
1.04 (1.03-1.05) <0.0001 
 





1.42 (1.12-1.81) 0.004 
 
1.44 (1.13-1.83) 0.003 
 
1.47 (1.13-1.90) 0.004 















1.40 (0.84-2.34) 0.198 
 
1.43 (0.83-2.48) 0.202 






1.39 (0.76-2.55) 0.283 
 
1.42 (0.77-2.62) 0.257 








0.75 (0.57-0.99) 0.044 








0.88 (0.66-1.17) 0.386 


























1.93 (1.48-2.52) <0.0001 
 
Table 4 Regression analyses of time to stroke with dialysis modality adjusted to a time dependent covariate. The following are presented: the unadjusted 
hazard ratio; model 1 – adjusted for age and sex; model 2 - adjusted for model 1 + factors influential to stroke and model 3 – model 2 + additional 
cardiovascular risk factors.   In all models use time on HD is associated with greater risk of stroke, HR 1.95-5.57, p<0.05. Abbreviations - HR, hazard ratio; 





Figure 1 Incidence rate of all stroke, split by starting RRT modality, Log-Rank test p<0.0001.   
 
